Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Retinoblastoma × Melphalan × Clear all

Phase

Phase 1 4 Phase NA 3 Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Myelodysplastic Syndromes 2 Multiple Myeloma 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Leukemia 2 Congenital Abnormalities 2 Anemia, Refractory, with Excess of Blasts 2 Waldenstrom Macroglobulinemia 1 Thrombocythemia, Essential 1 Sezary Syndrome 1 Retinoblastoma 1 Recurrence 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Neuroblastoma 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Prolymphocytic 1

Interventions

Vincristine 1 Topotecan 1 Platinum Compounds 1 Melphalan 1 Hyperthermia, Induced 1 Etoposide 1 Drug Therapy 1 Cryotherapy 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04681417 2025-11-28

RETINO 2018

Institut Curie

Phase 2/3 Recruiting

Other solid neoplasm

Retinoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡